Patients treated with gotistobart lived for a median 18.5 months, compared with 10 months for those given the standard-of-care chemotherapy.
Related stories
Gulf states postpone strait of Hormuz talks with Iran as Yemen conflict intensifies
Zelenskyy urges parliament to oust prosecutor general over graft turmoil
China dismisses AI slowdown calls and blasts ‘fearmongering’ from U.S. tech leaders
Why the Houthi advance towards Yemen’s Marib, Taiz matters
Temporary Hormuz solution deferred as Iran-Arab summit falls through
Poland pledges to strengthen security after drone strikes along border with Ukraine